Xeris Biopharma (XERS) Competitors

Xeris Biopharma logo
$3.59 -0.01 (-0.28%)
Closing price 02/14/2025 04:00 PM Eastern
Extended Trading
$3.60 +0.01 (+0.39%)
As of 02/14/2025 05:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

XERS vs. JANX, TARS, IDYA, AGIO, SDGR, NAMS, APGE, BLTE, TVTX, and IRON

Should you be buying Xeris Biopharma stock or one of its competitors? The main competitors of Xeris Biopharma include Janux Therapeutics (JANX), Tarsus Pharmaceuticals (TARS), IDEAYA Biosciences (IDYA), Agios Pharmaceuticals (AGIO), Schrödinger (SDGR), NewAmsterdam Pharma (NAMS), Apogee Therapeutics (APGE), Belite Bio (BLTE), Travere Therapeutics (TVTX), and Disc Medicine (IRON). These companies are all part of the "pharmaceutical products" industry.

Xeris Biopharma vs.

Xeris Biopharma (NASDAQ:XERS) and Janux Therapeutics (NASDAQ:JANX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation, profitability and community ranking.

Xeris Biopharma has a beta of 2.61, indicating that its share price is 161% more volatile than the S&P 500. Comparatively, Janux Therapeutics has a beta of 3.16, indicating that its share price is 216% more volatile than the S&P 500.

Xeris Biopharma received 102 more outperform votes than Janux Therapeutics when rated by MarketBeat users. However, 71.19% of users gave Janux Therapeutics an outperform vote while only 69.90% of users gave Xeris Biopharma an outperform vote.

CompanyUnderperformOutperform
Xeris BiopharmaOutperform Votes
144
69.90%
Underperform Votes
62
30.10%
Janux TherapeuticsOutperform Votes
42
71.19%
Underperform Votes
17
28.81%

In the previous week, Janux Therapeutics had 1 more articles in the media than Xeris Biopharma. MarketBeat recorded 2 mentions for Janux Therapeutics and 1 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 1.54 beat Janux Therapeutics' score of 1.16 indicating that Xeris Biopharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Xeris Biopharma
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Janux Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Xeris Biopharma currently has a consensus target price of $5.15, indicating a potential upside of 43.45%. Janux Therapeutics has a consensus target price of $89.90, indicating a potential upside of 147.18%. Given Janux Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Janux Therapeutics is more favorable than Xeris Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xeris Biopharma
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75
Janux Therapeutics
0 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
2 Strong Buy rating(s)
3.08

42.8% of Xeris Biopharma shares are held by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are held by institutional investors. 4.6% of Xeris Biopharma shares are held by insiders. Comparatively, 29.4% of Janux Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Xeris Biopharma has a net margin of -33.69% compared to Janux Therapeutics' net margin of -463.91%. Xeris Biopharma's return on equity of 0.00% beat Janux Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Xeris Biopharma-33.69% N/A -17.38%
Janux Therapeutics -463.91%-10.47%-9.86%

Janux Therapeutics has lower revenue, but higher earnings than Xeris Biopharma. Janux Therapeutics is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xeris Biopharma$163.91M3.27-$62.26M-$0.45-7.98
Janux Therapeutics$8.08M236.22-$58.29M-$1.17-31.09

Summary

Janux Therapeutics beats Xeris Biopharma on 12 of the 19 factors compared between the two stocks.

Get Xeris Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for XERS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

XERS vs. The Competition

MetricXeris BiopharmaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$535.20M$6.83B$5.76B$9.21B
Dividend YieldN/A2.90%5.27%3.99%
P/E Ratio-7.989.2825.5919.43
Price / Sales3.27324.30469.2576.00
Price / CashN/A75.4646.0638.90
Price / Book-71.805.537.305.05
Net Income-$62.26M$123.46M$3.19B$222.81M
7 Day Performance0.56%1.37%1.69%1.29%
1 Month Performance12.19%2.09%4.12%1.52%
1 Year Performance11.49%1.28%22.23%16.53%

Xeris Biopharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
XERS
Xeris Biopharma
3.9139 of 5 stars
$3.59
-0.3%
$5.15
+43.5%
+11.5%$535.20M$163.91M-7.98290
JANX
Janux Therapeutics
3.7955 of 5 stars
$37.80
-4.0%
$89.90
+137.8%
+285.7%$1.98B$8.08M-32.3130Positive News
TARS
Tarsus Pharmaceuticals
1.3505 of 5 stars
$51.76
-2.2%
$56.00
+8.2%
+63.6%$1.98B$17.45M-13.5950
IDYA
IDEAYA Biosciences
3.6893 of 5 stars
$22.42
-2.5%
$53.67
+139.4%
-55.4%$1.94B$23.39M-9.6280Earnings Report
Analyst Forecast
Analyst Revision
AGIO
Agios Pharmaceuticals
4.2447 of 5 stars
$33.97
+1.5%
$56.33
+65.8%
+25.3%$1.94B$26.82M2.99390Earnings Report
Analyst Downgrade
Short Interest ↓
SDGR
Schrödinger
2.1591 of 5 stars
$25.18
-1.9%
$32.11
+27.5%
-23.5%$1.83B$216.67M-10.76790Positive News
NAMS
NewAmsterdam Pharma
3.4162 of 5 stars
$19.26
-4.6%
$41.60
+116.0%
-3.9%$1.78B$14.09M0.004
APGE
Apogee Therapeutics
2.5885 of 5 stars
$39.35
-0.9%
$89.71
+128.0%
+1.7%$1.77BN/A-16.2691
BLTE
Belite Bio
3.473 of 5 stars
$53.80
-6.5%
$96.33
+79.1%
+17.6%$1.66BN/A-48.4710Short Interest ↓
TVTX
Travere Therapeutics
2.4491 of 5 stars
$21.10
-3.0%
$24.00
+13.7%
+179.4%$1.65B$145.24M-4.64460
IRON
Disc Medicine
2.0913 of 5 stars
$54.71
-0.2%
$88.90
+62.5%
-17.9%$1.63BN/A-13.7530Short Interest ↑

Related Companies and Tools


This page (NASDAQ:XERS) was last updated on 2/17/2025 by MarketBeat.com Staff
From Our Partners